Rational Combinations 360° Speakers
Kenneth Hance, PhD, MPH
Director, Antibody Therapies, Immuno-Oncology & Combinations Discovery Performance Unit
Kenneth Hance, PhD, MPH, has worked in the field of Cancer Immunology for 15 years and currently serves as the Director of Antibody Therapies in the Immuno-Oncology and Combinations Discovery Performance Unit at GlaxoSmithKline. In this role, he is responsible for delivering critical path biology to support a growing portfolio of immune-based therapies within GSK Oncology including the discovery and validation of monoclonal and bispecific antibodies. Dr Hance also has a joint appointment as a Visiting Scientist at the Wistar Institute in Philadelphia, PA. Prior to joining GSK, Dr Hance worked in the biopharmaceutical division of Merck KGaA where he contributed to the development of the recently approved anti-PD-L1 antibody (Bavencio (Avelumab)) and the clinical stage anti-PD-L1/TGF-βRII bispecific antibody (M7824). Dr Hance received his postdoctoral training in the Laboratory of Tumor Immunology and Biology at the National Cancer Institute.